Cargando…

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis

BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others. The characteristics of pwMS developing re-emerging disease activity r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen-Philbey, Kimberley, De Trane, Stefania, MacDougall, Amy, Adams, Ashok, Bianchi, Lucia, Campion, Thomas, Giovannoni, Gavin, Gnanapavan, Sharmilee, Holden, David W., Marta, Monica, Mathews, Joela, Turner, Benjamin P., Baker, David, Schmierer, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638874/ https://www.ncbi.nlm.nih.gov/pubmed/37954917 http://dx.doi.org/10.1177/17562864231200627

Ejemplares similares

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
por: Adams, Ashok, et al.
Publicado: (2022)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
por: Reyes, Saúl, et al.
Publicado: (2020)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation
por: Keddie, Stephen, et al.
Publicado: (2018)

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains
por: Saxena, Gauri K., et al.
Publicado: (2020)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
por: Gnanapavan, Sharmilee, et al.
Publicado: (2014)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Both cladribine and alemtuzumab may effect MS via B-cell depletion
por: Baker, David, et al.
Publicado: (2017)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Progression in multiple sclerosis is associated with low endogenous NCAM
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β
por: Lee, Paul R., et al.
Publicado: (2017)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
por: Kalatskaya, Irina, et al.
Publicado: (2023)

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
por: Allen-Philbey, Kimberley, et al.
Publicado: (2020)

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
por: Mahler, Christoph, et al.
Publicado: (2020)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2021)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0kotgrslsa036i7l002ql2h0fa